DETECTING CANCER EARLY TO IMPROVE PATIENT TREATMENT STRATEGIES AND SAVE LIVES

Customer: Biodesix

Streck and Biodesix partner to ensure liquid biopsy samples are kept stable, for accurate early cancer detection.

Problem

During transportation, liquid biopsy samples can become unstable, which can lead to contamination from degrading white blood cells. This contamination reduces the sensitivity of cfDNA analysis, making it difficult to accurately detect cancer-associated nucleic acids.

Solution

Streck offers a range of stabilization products, including Cell-Free DNA BCT®, Nucleic Acid BCT™ (for research use only), and Protein Plus BCT™ (for research use only), to maintain the integrity of blood samples.

Outcome

The collaboration between Biodesix and Streck has enhanced the reliability and effectiveness of liquid biopsies. This partnership has allowed for improved detection of cancer-associated nucleic acids, resulting in more accurate diagnostic evaluations. This innovation can also enable more comprehensive analyses from smaller blood samples and ultimately benefit patients with critical conditions.

203

203 patents that help save lives through early cancer detection.